Differentiating inhibition selectivity and binding affinity of isocitrate dehydrogenase 1 variant inhibitors
Isocitrate dehydrogenase (IDH) 1/2 gain-of-function variants catalyze the production of the oncometabolite 2-hydroxyglutarate and are validated targets for leukemia treatment. We report binding and inhibition studies on 13 IDH1/2 variant inhibitors, including clinical candidates and drugs, with wild...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Jezik: | English |
| Izdano: |
American Chemical Society
2023
|
| Teme: |